COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00890045
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : August 19, 2014
CryoLife, Inc.
Information provided by (Responsible Party):
Hemosphere, Inc.

Brief Summary:
Compare the HeRO Vascular Access Device to a conventional ePTFE graft.

Condition or disease Intervention/treatment Phase
Renal Failure Chronic Requiring Hemodialysis Device: HeRO Vascular Access Device Device: Conventional ePTFE hemodialysis graft Not Applicable

Detailed Description:
The purpose of this study is to compare the HeRO Vascular Access Device to a conventional ePTFE graft. It is hypothesized that HeRO patency will be comparable to the conventional ePTFE graft control.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison Between the HeRO® Graft and Conventional Arteriovenous Grafts in Hemodialysis Patients
Study Start Date : July 2004
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

Arm Intervention/treatment
Active Comparator: Control graft
Conventional ePTFE hemodialysis graft
Device: Conventional ePTFE hemodialysis graft
Conventional ePTFE hemodialysis graft

Experimental: HeRO Vascular Access Device
HeRO Vascular Access Device
Device: HeRO Vascular Access Device
HeRO Vascular Access Device

Primary Outcome Measures :
  1. Loss of HeRO secondary patency compared to control [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Loss of HeRO primary patency compared to control [ Time Frame: 12 months ]
  2. HeRO serious device or implant procedure-related adverse events compared to control [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 21 years of age or older.
  2. Male or non-pregnant female.
  3. Life expectancy 2 years.
  4. End-stage renal disease requiring an arm vascular prosthesis for dialysis access.
  5. Ability to understand and provide written informed consent.
  6. Willing and able to cooperate with follow-up examinations.
  7. Subject's upper arm can be used for implant (Note: The GVAS device must be implanted in the upper arm only, but the Control group graft can be implanted in the upper or lower arm location.).
  8. Able to follow a daily aspirin and/or other oral anticoagulation/antiplatelet regimen.

Exclusion Criteria:

  1. Potential graft target artery less than 3 mm in diameter determined by any suitable preoperative measure.
  2. Documented history of drug abuse within six months.
  3. "Planned" concomitant surgical procedure or previous major surgery within 30 days, excluding vascular access related procedures.
  4. Currently being treated with another investigational device or drug.
  5. Known bleeding diathesis or hypercoagulable state.
  6. Peripheral white blood cell count 1500/mm3 (1.5 K/mm3) or platelet counts 50,000/mm3 (50 K/mm3).
  7. Degenerative connective tissue disease, e.g., Marfan's and Ehlers Danlos Syndrome. Subjects with Lupus Erythematosus may be included.
  8. Subjects with known or suspected concomitant bacterial, fungal, viral, or parasitic infection. Subjects with Hepatitis B may be included. Subjects who are HIV + with CD4 count of <200 are excluded.
  9. Severe underlying co-morbidity or immediate life-threatening condition.
  10. Subjects with any condition which, in the opinion of the investigator, could preclude evaluation of response or completion of follow-up or affect subject safety.
  11. Subjects who are candidates for autologous fistulas.
  12. Subjects with scheduled renal transplant within the next 12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00890045

Layout table for location information
United States, California
St. Vincent's Medical Center
Los Angeles, California, United States, 90057
United States, Florida
University of Miami/Cedars Medical Center
Miami, Florida, United States, 33125
United States, Georgia
St. Joseph's Hospital
Atlanta, Georgia, United States, 30342
United States, Illinois
Southern Illinois Unversity
Springfield, Illinois, United States, 62702
United States, Maryland
Holy Cross Hospital
Rockville, Maryland, United States, 20852
United States, Minnesota
North Memorial Medical Center
Robbinsdale, Minnesota, United States, 55422
United States, North Carolina
Duke Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
Seton/Brackenridge Hospitals
Austin, Texas, United States, 78703
Baylor Medical Center/Methodist Hospital
Houston, Texas, United States, 77030
Baptist Medical Center
San Antonio, Texas, United States, 78205
United States, Virginia
Sentara Heart Hospital
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Hemosphere, Inc.
CryoLife, Inc.
Layout table for investigator information
Principal Investigator: Marc Glickman, MD Sentara Heart Hospital, Norfolk, VA
Publications of Results:
Layout table for additonal information
Responsible Party: Hemosphere, Inc. Identifier: NCT00890045    
Other Study ID Numbers: 11-0004
First Posted: April 29, 2009    Key Record Dates
Last Update Posted: August 19, 2014
Last Verified: August 2014
Keywords provided by Hemosphere, Inc.:
Vascular access hemodialysis
ePTFE graft
Long-term vascular access for hemodialysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic